Orthofix Medical (NASDAQ:OFIX) Given New $20.00 Price Target at Canaccord Genuity Group

Orthofix Medical (NASDAQ:OFIX) had its target price trimmed by Canaccord Genuity Group from $24.00 to $20.00 in a research report report published on Thursday morning,Benzinga reports. The firm currently has a buy rating on the medical device company’s stock.

A number of other equities analysts have also weighed in on OFIX. TD Cowen began coverage on Orthofix Medical in a research report on Tuesday, January 27th. They issued a “hold” rating and a $14.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Orthofix Medical in a research note on Thursday, January 22nd. Finally, Barrington Research lowered their price objective on shares of Orthofix Medical from $18.00 to $17.00 and set an “outperform” rating on the stock in a research report on Wednesday. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Orthofix Medical presently has a consensus rating of “Hold” and a consensus price target of $18.25.

Orthofix Medical Price Performance

Shares of NASDAQ OFIX opened at $13.17 on Thursday. The firm has a market cap of $521.53 million, a P/E ratio of -5.63 and a beta of 0.78. Orthofix Medical has a twelve month low of $10.24 and a twelve month high of $18.66. The company has a quick ratio of 1.38, a current ratio of 2.45 and a debt-to-equity ratio of 0.39. The company has a 50 day moving average of $14.12 and a 200 day moving average of $14.70.

Orthofix Medical (NASDAQ:OFIX) last posted its earnings results on Tuesday, February 24th. The medical device company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of $0.44 by ($0.50). Orthofix Medical had a negative return on equity of 20.38% and a negative net margin of 11.21%.The business had revenue of $219.91 million during the quarter, compared to the consensus estimate of $218.72 million. As a group, research analysts expect that Orthofix Medical will post -2.81 EPS for the current fiscal year.

Insider Activity at Orthofix Medical

In related news, CEO Massimo Calafiore sold 9,797 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $15.21, for a total transaction of $149,012.37. Following the completion of the sale, the chief executive officer directly owned 217,237 shares in the company, valued at approximately $3,304,174.77. The trade was a 4.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Julie Andrews sold 4,873 shares of the company’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $14.38, for a total transaction of $70,073.74. Following the sale, the chief financial officer directly owned 58,039 shares of the company’s stock, valued at approximately $834,600.82. This represents a 7.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 24,270 shares of company stock worth $370,958. 1.30% of the stock is owned by company insiders.

Institutional Trading of Orthofix Medical

Several hedge funds have recently bought and sold shares of OFIX. Paradigm Capital Management Inc. NY raised its stake in shares of Orthofix Medical by 34.6% in the second quarter. Paradigm Capital Management Inc. NY now owns 3,340,600 shares of the medical device company’s stock worth $37,248,000 after buying an additional 858,900 shares during the period. Millennium Management LLC increased its holdings in Orthofix Medical by 86.6% in the 3rd quarter. Millennium Management LLC now owns 1,475,718 shares of the medical device company’s stock worth $21,605,000 after acquiring an additional 684,850 shares in the last quarter. Juniper Investment Company LLC raised its stake in Orthofix Medical by 23.3% during the 4th quarter. Juniper Investment Company LLC now owns 3,510,333 shares of the medical device company’s stock worth $53,217,000 after acquiring an additional 663,278 shares during the period. Bank of America Corp DE lifted its holdings in Orthofix Medical by 659.5% during the second quarter. Bank of America Corp DE now owns 687,410 shares of the medical device company’s stock valued at $7,665,000 after purchasing an additional 596,907 shares in the last quarter. Finally, Engine Capital Management LP boosted its position in shares of Orthofix Medical by 13.6% in the second quarter. Engine Capital Management LP now owns 4,251,671 shares of the medical device company’s stock worth $47,406,000 after purchasing an additional 510,281 shares during the period. Institutional investors own 89.76% of the company’s stock.

Trending Headlines about Orthofix Medical

Here are the key news stories impacting Orthofix Medical this week:

• Positive Sentiment: Engine Capital (a major shareholder) purchased 124,797 shares at an average $12.55 (a ~3.53% increase in its stake), signaling confidence from an activist holder; filing: SEC Filing
• Positive Sentiment: Engine Capital added another 13,061 shares at ~$12.96, a smaller follow-on buy that further increases their total stake — another sign an influential holder is accumulating. SEC Filing
• Neutral Sentiment: Coverage pieces and earnings summaries are reframing the story: analysts and outlets are highlighting margin timing issues and updated 2026 guidance, moving the narrative from near-term margin pressure to longer-term channel optimization. Article
• Neutral Sentiment: Multiple outlet earnings summaries and call write-ups detail that revenue was roughly in line but margins missed, providing context for management’s updated timeline for reaching its 6.5%–7.5% sales CAGR through 2028. Seeking Alpha
• Negative Sentiment: Q4 EPS missed materially (reported -$0.06 vs. $0.44 expected), which caused an immediate share pullback and remains the principal near-term negative catalyst. Earnings Miss
• Negative Sentiment: Analysts cut price targets after results: Canaccord trimmed its target from $24 to $20 but maintained a buy rating, and Barrington lowered its target from $18 to $17 (outperform). These reductions limit near-term upside expectations despite positive ratings. Benzinga

About Orthofix Medical

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.